MYLAN BARRED FROM SELLING GENERIC TOPAMAX

MAY 01, 2007

A federal judge in New Jersey issued an injunction permanently barring Mylan Pharmaceuticals from selling generic topiramate tablets and capsules in the United States before September 26, 2008, the expiration date of the patent for TOPAMAX (topiramate) held by Ortho-McNeil Neurologics Inc. Mylan had challenged the validity of that patent and filed an abbreviated new drug application to market a generic version of the epilepsy drug. The branded manufacturer countered with a patent infringement complaint against Mylan and obtained a preliminary injunction against the generic firm last fall.




SHARE THIS SHARE THIS
0
 

Conference Coverage

Check back here regularly for live conference coverage from the American Academy of Pain Medicine and the upcoming American Pharmacists Association Meeting and Expo. 


 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.